Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. Stock Boards ›
  4. Innovation Pharmaceuticals Inc (IPIX) Message Board

BEVERLY, Mass., Oct. 31, 2017 (GLOBE NEWSWIRE) --

Message Board Public Reply | Private Reply | Keep | Replies (3)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 72447
(Total Views: 309)
Posted On: 10/31/2017 11:06:39 AM
Avatar
Posted By: Drano
Re: 4kids #38799
BEVERLY, Mass., Oct. 31, 2017 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals
Inc. (OTCQB:IPIX) ( the Company ), a clinical stage biopharmaceutical company,
is pleased to report continued developments in its dermatology franchise.
The Company s randomized, placebo-controlled Phase 2b clinical trial of Prurisol
for chronic, moderate-to-severe plaque psoriasis (see NCT02949388), enrolling a
total of 199 patients, remains on-track for completion in December. Separately,
building upon promising results seen to date demonstrating its
anti-inflammatory, anti-infective and immunomodulatory properties, the Company
is looking to expand Brilacidin into treating multiple serious chronic skin
diseases. The Company plans to participate in upcoming dermatology conferences,
including as a sponsor in this week s Symposium on Hidradenitis Suppurativa
Advances to be held November 4-5, 2017, in Detroit, MI.
Brilacidin s potential application in dermatology to provide improved treatment options for people in need is discussed below.
From a scientific perspective, defensins which Brilacidin was designed to
mimic play an important and multifunctional role in regulating the skin
micro-environment. The increased susceptibility of people with Atopic Dermatitis
(Eczema) to S. aureus infections, significantly complicating this skin condition
and against which Brilacidin has been shown to have potent efficacy, is thought
to be influenced by the impaired expression of Host Defense Proteins (HDPs). Up
to a combined 50 million people, in the U.S. and major European markets, are
affected by Eczema. Brilacidin also exhibits strong anti-inflammatory effects on
key effector cells involved in the etiology of Hidradenitis Suppurativa (HS), a
burdensome skin disease affecting 1 to 4 percent of the world s population, and
for which there currently is only one approved marketed treatment (Humira).
Brilacidin s antimicrobial and wound healing properties might similarly benefit
HS sufferers. Pre-clinical lab work also indicates impressive Minimum Inhibitory
Concentration (MIC) values when Brilacidin was tested against Propionibacterium
spp. a type of bacteria expressed in Acne compared to other antibiotics, such as
Erythromycin, Clindamycin, Minocycline, Doxycycline and Metronidazole.
One key aspect of Brilacidin s Mechanism of Action, inhibiting Phosphodiesterase
4 (PDE4), might also contribute to its therapeutic potential in treating skin
diseases.
Linked below is additional information, published on the Company s website, elaborating on Brilacidin s treatment potential in various dermatological conditions.
Brilacidin s Potential Application in Dermatology http://www.ipharminc.com/new-blog/2017/6/5/br...ermatology The Clinical Need and Market Opportunity in Atopic Dermatitis http://www.ipharminc.com/new-blog/2017/6/21/t...dermatitis Toward Developing Newer Treatments for Hidradenitis Suppurativa http://www.ipharminc.com/new-blog/2017/5/30/h...ne-inversa
About Prurisol


(7)
(0)




Innovation Pharmaceuticals Inc (IPIX) Stock Research Links


  1.  
  2.  


  3.  
  4.  
  5.  






Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us